Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Cirrhosis
  Free Subscription

Articles published in
J Gastroenterol Hepatol
    April 2026
  1. GAO A, Luo J, Ye X, Hu Y, et al
    Comments on "Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort".
    J Gastroenterol Hepatol. 2026 Apr 17. doi: 10.1111/jgh.70395.
    >> Share

  2. WANG ZV, Boumelhem BB, Pennell T, Bachovchin WW, et al
    A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:1311-1322.
    >> Share

    March 2026
  3. JINATO T, Sikaroodia M, Gilleveta PM, Dissayabutra T, et al
    Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort.
    J Gastroenterol Hepatol. 2026 Mar 30. doi: 10.1111/jgh.70358.
    >> Share

  4. KIM MN
    Reply Letter to: A Critical Assessment of "Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis".
    J Gastroenterol Hepatol. 2026 Mar 25. doi: 10.1111/jgh.70335.
    >> Share

  5. MIN EK, Kim SS, Ahn B, Kim DG, et al
    Diagnostic Value of MR Elastography and MRI-Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology.
    J Gastroenterol Hepatol. 2026 Mar 13. doi: 10.1111/jgh.70316.
    >> Share

  6. MUJAHID MUF, Haider E
    A Critical Assessment of "Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis".
    J Gastroenterol Hepatol. 2026 Mar 7. doi: 10.1111/jgh.70328.
    >> Share

  7. HSIEH ML, Su TH, Lin YC, Chen YY, et al
    Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:1041-1051.
    >> Share

  8. LI Y, Li J, Dullaart RPF, Moshage H, et al
    Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases.
    J Gastroenterol Hepatol. 2026;41:880-894.
    >> Share

    February 2026
  9. O'HARA SP, Bogert PT, Dickinson S, Chen X, et al
    Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression.
    J Gastroenterol Hepatol. 2026 Feb 13. doi: 10.1111/jgh.70279.
    >> Share

  10. JANG TY
    Interaction Between Genetic Variants and Air Pollution and the Risk of Hepatocellular Carcinoma in Cirrhotic Patients.
    J Gastroenterol Hepatol. 2026 Feb 6. doi: 10.1111/jgh.70282.
    >> Share

  11. DENG X, Huang N, Du K, Zhang H, et al
    The Spleen Promotes Liver Sinusoidal Endothelial Cell Angiogenesis by Stimulating the TGFbeta/Smad2/3 Pathway Through GDF15.
    J Gastroenterol Hepatol. 2026;41:774-786.
    >> Share

    January 2026
  12. XU J, Ma H, Yang W, Tu R, et al
    ATF3 Mediates the Immunoregulatory Role of the Tim-3 Pathway in Primary Biliary Cholangitis.
    J Gastroenterol Hepatol. 2026 Jan 15. doi: 10.1111/jgh.70234.
    >> Share

  13. MAK LY, Lai JC, Liu K, Lui R, et al
    Chronic Hepatitis B Infection: Patient Guidance.
    J Gastroenterol Hepatol. 2026;41:61-77.
    >> Share

  14. LIM AH, Litwin PS, Dionela W, Tse E, et al
    Endoscopic Ultrasound Guided Portal Pressure Gradient Measurement in Predicting Outcomes of Abdominal Surgery in Patients With Chronic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:286-292.
    >> Share

  15. HUANG YC, Wang CW, Huang JC, Liang PC, et al
    FIB-4 Serves as a Referral Index for Coronary Artery Calcification in Patients With MASLD.
    J Gastroenterol Hepatol. 2026;41:332-340.
    >> Share

    December 2025
  16. LIU Z, Jiang H, Li F, Xie R, et al
    Bile Acid Metabolites Control Th17/Treg Balance in Primary Biliary Cholangitis: Mechanisms of Disease Progression and Therapeutic Targets.
    J Gastroenterol Hepatol. 2025 Dec 7. doi: 10.1111/jgh.70189.
    >> Share

  17. SATO S, Kawai H, Yamaguchi M, Nago H, et al
    Fibrosis in Asymptomatic Steatotic Liver Disease With Normal Alanine Aminotransferase: Analysis of 2448 Health Check-Up Cohort by Ultrasound Attenuation Imaging and Shear Wave Elastography.
    J Gastroenterol Hepatol. 2025;40:2987-2996.
    >> Share

  18. YU H, Wu J, Li M, Hu C, et al
    Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues.
    J Gastroenterol Hepatol. 2025;40:2963-2975.
    >> Share

    November 2025
  19. CHEN YC, Chang YP, Lee JY, Chen CY, et al
    Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2025 Nov 14. doi: 10.1111/jgh.70160.
    >> Share

    October 2025
  20. FAN C, He X, Zhou Y, Ye C, et al
    The Effects of CD100 Stimulation on Primary Human Hepatocytes (PHHs) and Its Implications in HBV-Related Liver Cirrhosis.
    J Gastroenterol Hepatol. 2025 Oct 21. doi: 10.1111/jgh.70123.
    >> Share

  21. AGARWAL A, Pachisia AV, Agarwal S, Mehta S, et al
    Celiac Disease and Its Impact on Liver-Related Outcomes in Patients With All-Cause Cirrhosis: The CELIHEP Study.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70082.
    >> Share

  22. XU L, Liu J
    Comment on Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70114.
    >> Share

  23. KIM MN, Park GU, You SC, Lee JS, et al
    Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis.
    J Gastroenterol Hepatol. 2025 Oct 1. doi: 10.1111/jgh.70078.
    >> Share

  24. SHI H, Dou D, Zhang F, Du Y, et al
    Prevalence and Bidirectional Association Between Autoimmune Liver Disease and Inflammatory Bowel Disease: A Meta-Analysis.
    J Gastroenterol Hepatol. 2025;40:2362-2372.
    >> Share

  25. ZENG X, Li Z, Chen Y, Yao H, et al
    Impairing Islets in Newborn Mice Promotes Liver Fibrosis and Carcinoma Development in a Rapid NASH Model.
    J Gastroenterol Hepatol. 2025;40:2601-2612.
    >> Share

    September 2025
  26. ABREU ES, Fernandes GP, Lacerda HC, Reginato PH, et al
    Efficacy and Safety of Obeticholic Acid as Second-Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025 Sep 30. doi: 10.1111/jgh.70094.
    >> Share

    August 2025
  27. HEGAZY RA
    Unraveling Liver Cirrhosis: Bridging Pathophysiology to Innovative Therapeutics.
    J Gastroenterol Hepatol. 2025 Aug 3. doi: 10.1111/jgh.70037.
    >> Share

    July 2025
  28. CHEN Y, Zhai D, Shen J, Hu W, et al
    Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
    J Gastroenterol Hepatol. 2025 Jul 26. doi: 10.1111/jgh.70003.
    >> Share

  29. JANG TY, Wang CW, Liang PC, Wei YJ, et al
    Steatotic Liver Disease-Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog-Treated Chronic Hepatitis B.
    J Gastroenterol Hepatol. 2025 Jul 24. doi: 10.1111/jgh.70021.
    >> Share

    June 2025
  30. CAINES A, Lu M, Wu T, Trudeau S, et al
    Pre-Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis.
    J Gastroenterol Hepatol. 2025 Jun 23. doi: 10.1111/jgh.17035.
    >> Share

  31. WANG L, Zhao Y, Duan B, Wang Y, et al
    Iron Quantification Using Spectral CT-Based Material Decomposition Technique for Noninvasive Hepatic Fibrosis Staging: An Experimental Study.
    J Gastroenterol Hepatol. 2025 Jun 4. doi: 10.1111/jgh.17031.
    >> Share

  32. XIA Y, Tie J, Wang G, Wu H, et al
    Benefits of TIPS for Patients With Large Ascites Preceding Recurrent or Refractory ascites: A Multicenter Cohort Study.
    J Gastroenterol Hepatol. 2025;40:1574-1585.
    >> Share

    May 2025
  33. MATSUBARA Y, Tsuboi A, Shigenobu S, Hirata I, et al
    Clinical Significance of Small-Bowel Mucosal Changes in Liver Cirrhosis Patients With Suspected Small-Bowel Bleeding: A Capsule Endoscopy Study.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.17002.
    >> Share

  34. JOSHI A, Raja HAA, Roy P, Latif F, et al
    Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta-Analysis.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.16999.
    >> Share

    April 2025
  35. TAMAKI N, Huang DQ, Lee HW, Park SY, et al
    Head-to-Head Comparison of Long-Term HCC Risk of Antivirals-Treated Versus Untreated Low-Level Viremia in HBV-Compensated Cirrhosis.
    J Gastroenterol Hepatol. 2025 Apr 27. doi: 10.1111/jgh.16986.
    >> Share

  36. OGAWA E, Kawano A, Kohjima M, Koyanagi T, et al
    Long-Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct-Acting Antivirals.
    J Gastroenterol Hepatol. 2025;40:971-978.
    >> Share

    March 2025

  37. Correction to 'Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance'.
    J Gastroenterol Hepatol. 2025 Mar 14. doi: 10.1111/jgh.16918.
    >> Share

  38. JAFARI-KHORCHANI M, Pantopoulos K, Zare-Mehrjardi MJ, Allameh A, et al
    Sequential Changes in NOX4 Expression, Oxidative Stress Indices, PIIINP, and Liver Histopathology During Hepatocellular Carcinogenesis Induced in Mice.
    J Gastroenterol Hepatol. 2025 Mar 3. doi: 10.1111/jgh.16914.
    >> Share

  39. JIANG H, Yu H, Huang Y, Li M, et al
    Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase.
    J Gastroenterol Hepatol. 2025;40:720-730.
    >> Share

  40. JAYABALAN D, Huang Y, Calzadilla-Bertot L, Adams LA, et al
    Natural History and Predictors of Clinical Outcomes in Autoimmune Liver Diseases: A Multicenter Study.
    J Gastroenterol Hepatol. 2025;40:731-740.
    >> Share

    February 2025
  41. GIRI S, Ingawale S, Khatana G, Gore P, et al
    Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia-Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021.
    J Gastroenterol Hepatol. 2025 Feb 27. doi: 10.1111/jgh.16922.
    >> Share

  42. NAKAKUKI N, Maekawa S, Takano S, Osawa L, et al
    TCR Repertoire Analysis During Therapeutic Interventions in Liver Diseases Using Next-Generation Sequencing.
    J Gastroenterol Hepatol. 2025;40:537-547.
    >> Share

    January 2025
  43. PENG J, Zhang L, Dong Y, Long W, et al
    Factors Influencing Liver Cirrhosis Progression in Wilson's Disease Patients: A Retrospective Cohort Study Over 5 Years.
    J Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1111/jgh.16889.
    >> Share

  44. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Validation of serum non-invasive tests of liver fibrosis as prognostic markers of clinical outcomes in people with fatty liver disease in Australia.
    J Gastroenterol Hepatol. 2025;40:241-249.
    >> Share

    December 2024
  45. MALANDRIS K, Arampidis D, Mainou M, Papadopoulos N, et al
    FibroScan-AST score for diagnosing fibrotic MASH: A systematic review and meta-analysis of diagnostic test accuracy studies.
    J Gastroenterol Hepatol. 2024;39:2582-2591.
    >> Share

  46. PAN L, Wang L, Ma H, Ding F, et al
    Relevance of combined influence of nutritional and inflammatory status on non-alcoholic fatty liver disease and advanced fibrosis: A mediation analysis of lipid biomarkers.
    J Gastroenterol Hepatol. 2024;39:2853-2862.
    >> Share

  47. KIM K, Lee Y, Lee JS, Kim MN, et al
    Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study.
    J Gastroenterol Hepatol. 2024;39:2845-2852.
    >> Share

  48. CHANG ML, Le PH, Chen WT, Chen TD, et al
    Distinct characteristics of various autoimmune liver diseases: A 22-year hospital-based study in Taiwan.
    J Gastroenterol Hepatol. 2024;39:2835-2844.
    >> Share

  49. MAK LY, Hui RW, Chung MSH, Wong DK, et al
    Regression of liver fibrosis after HBsAg loss: A prospective matched case-control evaluation using transient elastography and serum enhanced liver fibrosis test.
    J Gastroenterol Hepatol. 2024;39:2826-2834.
    >> Share

    November 2024
  50. JAROENLAPNOPPARAT A, Prasitsumrit V, Ponvilawan B, Waitayangkoon P, et al
    Clostridioides difficile infection increases in-hospital mortality, length of stay, and hospital cost but not 30-day mortality in cirrhotic patients.
    J Gastroenterol Hepatol. 2024 Nov 13. doi: 10.1111/jgh.16807.
    >> Share

  51. ZENG X, Liao Y, Cheng W
    Transient receptor potential channel 6 knockout ameliorates hepatic fibrosis by inhibiting the activation and proliferation of hepatic stellate cells.
    J Gastroenterol Hepatol. 2024 Nov 7. doi: 10.1111/jgh.16802.
    >> Share

  52. CHANG YP, Liu CH, Huang CB, Lee JY, et al
    Serum Mac-2 binding protein glycosylation isomer dynamics in patients achieving sustained virologic response for hepatitis C virus.
    J Gastroenterol Hepatol. 2024;39:2439-2446.
    >> Share

  53. WONGTRAKUL W, Niltwat S, Charatcharoenwitthaya N, Karaketklang K, et al
    Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:2299-2307.
    >> Share

    October 2024
  54. PRINCE DS, Hoque S, Kim C, Maher S, et al
    Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance.
    J Gastroenterol Hepatol. 2024 Oct 24. doi: 10.1111/jgh.16782.
    >> Share

  55. LI Y, Chen L, Li S, Song H, et al
    The m6A reader IGF2BP1 contributes to the activation of hepatic stellate cells through facilitating TUBB4B mRNA stabilization.
    J Gastroenterol Hepatol. 2024 Oct 15. doi: 10.1111/jgh.16765.
    >> Share

  56. LEOW YW, Chan WL, Lai LL, Mustapha NRN, et al
    LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:2182-2189.
    >> Share

  57. YU H, Huang Y, Li M, Jiang H, et al
    Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease.
    J Gastroenterol Hepatol. 2024;39:2169-2181.
    >> Share

  58. YANG J, Choi WM, Lee D, Shim JH, et al
    Revisiting the steatosis-associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability.
    J Gastroenterol Hepatol. 2024;39:2112-2119.
    >> Share

  59. ALATAS FS, Yamaza T, Matsuura T, Ongko L, et al
    Potential role of stem cells from human exfoliated deciduous teeth in inducing liver regeneration.
    J Gastroenterol Hepatol. 2024;39:2190-2196.
    >> Share

    September 2024
  60. PASSOS PRC, Filho VOC, Noronha MM, Hyppolito EB, et al
    Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Sep 25. doi: 10.1111/jgh.16752.
    >> Share

    August 2024
  61. BANERJEE A, Blinston D, Narain MA
    Inhibition of liver fibrosis by TET1 may be B cell mediated: Supporting evidence from a case of TNFAIP3 deficiency.
    J Gastroenterol Hepatol. 2024;39:1706-1707.
    >> Share

    July 2024
  62. MALANDRIS K, Papandreou S, Vasilakou D, Kakotrichi P, et al
    Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis.
    J Gastroenterol Hepatol. 2024;39:1219-1229.
    >> Share

    June 2024
  63. MALIK S, Tenorio BG, Moond V, Dahiya DS, et al
    Systematic review of machine learning models in predicting the risk of bleed/grade of esophageal varices in patients with liver cirrhosis: A comprehensive methodological analysis.
    J Gastroenterol Hepatol. 2024 Jun 17. doi: 10.1111/jgh.16645.
    >> Share

  64. WURSTLE S, Schneider T, Karapetyan S, Hapfelmeier A, et al
    LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic liver and infected ascites.
    J Gastroenterol Hepatol. 2024 Jun 5. doi: 10.1111/jgh.16637.
    >> Share

  65. LEE JS, Lee HW, Kim MN, Kim BK, et al
    Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center.
    J Gastroenterol Hepatol. 2024;39:1155-1163.
    >> Share

    May 2024
  66. HAYASHI M, Abe K, Sugaya T, Takahata Y, et al
    A low baseline serum myostatin concentration is associated with poor clinical outcome in patients with primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 May 30. doi: 10.1111/jgh.16639.
    >> Share

  67. SUN Z, Guo Y, Xu X, Zhou C, et al
    Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway.
    J Gastroenterol Hepatol. 2024 May 28. doi: 10.1111/jgh.16635.
    >> Share

  68. LIM J, Kim JH, Kim SE, Han SK, et al
    Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort.
    J Gastroenterol Hepatol. 2024 May 8. doi: 10.1111/jgh.16591.
    >> Share

  69. ENDO K, Kakisaka K, Abe T, Yusa K, et al
    Positive impact of obesity on the prognosis of liver cirrhosis.
    J Gastroenterol Hepatol. 2024 May 3. doi: 10.1111/jgh.16590.
    >> Share

  70. LEE S, Choi J, Park JH, Lim CY, et al
    Dynamic liver volume change in predicting hepatic decompensation and long-term effects of stereotactic body radiation therapy.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16588.
    >> Share

  71. MAKRI ES, Evripidou K, Polyzos SA
    Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2024;39:806-817.
    >> Share

    April 2024
  72. LIU Y, Hu Y, Li B, Su R, et al
    Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 Apr 12. doi: 10.1111/jgh.16547.
    >> Share

    March 2024
  73. WANG X, Liu H, Wang Y, Wang P, et al
    Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway.
    J Gastroenterol Hepatol. 2024 Mar 24. doi: 10.1111/jgh.16538.
    >> Share

    February 2024

  74. Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis".
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16529.
    >> Share

  75. WANG J, Zhang Y, Ma Y, Zhao S, et al
    TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443.
    >> Share

    January 2024
  76. AMJAD W, Jiang Z, Lai M
    Statin use in cirrhosis and its association with incidence of portal vein thrombosis.
    J Gastroenterol Hepatol. 2024 Jan 25. doi: 10.1111/jgh.16495.
    >> Share

  77. ZHU J, Xia Y, Liu X, Zhang C, et al
    Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16489.
    >> Share

  78. NIE MT, Wang PQ, Shi PM, Hong XL, et al
    Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16484.
    >> Share

    December 2023
  79. GOPAL P, Banerjee D, Karad A, Dandi K, et al
    Gastrointestinal: Congenital portosystemic shunt (Abernathy type 2) with cirrhosis of liver.
    J Gastroenterol Hepatol. 2023 Dec 26. doi: 10.1111/jgh.16456.
    >> Share

    November 2023
  80. SHI L, Feng G, Yang X, Zhang Y, et al
    Potential of PAQosome as a therapeutic target for hepatic fibrosis.
    J Gastroenterol Hepatol. 2023 Nov 28. doi: 10.1111/jgh.16427.
    >> Share

  81. ALLAIRE M, Thabut D
    The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16415.
    >> Share

    October 2023
  82. OH JH, Saeed WK, Kim HY, Lee SM, et al
    Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
    J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368.
    >> Share

  83. GIRI S, Singh A, Kolhe K, Kale A, et al
    Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378.
    >> Share

  84. ITO T, Morooka H, Takahashi H, Fujii H, et al
    Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
    J Gastroenterol Hepatol. 2023;38:1832-1839.
    >> Share

  85. SHAHRANI S, Gill SS, Sooi CY, Skantha R, et al
    Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease.
    J Gastroenterol Hepatol. 2023;38:1818-1822.
    >> Share

    September 2023
  86. KANG SH, Kim MY, Han SK, Baik SK, et al
    Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of decompensated cirrhosis.
    J Gastroenterol Hepatol. 2023 Sep 11. doi: 10.1111/jgh.16327.
    >> Share

  87. GASPAR R, Silva M, Cardoso P, Goncalves R, et al
    Spleen stiffness: a new tool to predict high-risk varices in cirrhotic patients.
    J Gastroenterol Hepatol. 2023 Sep 1. doi: 10.1111/jgh.16344.
    >> Share

    August 2023
  88. JIANG H, Xu N, Zhang W, Wei H, et al
    Do gut microbiome-targeted therapies improve liver function in cirrhotic patients? A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023 Aug 15. doi: 10.1111/jgh.16329.
    >> Share

  89. ANIRVAN P
    Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Aug 12. doi: 10.1111/jgh.16328.
    >> Share

  90. LI R, Liu J, Han P, Shi R, et al
    Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index.
    J Gastroenterol Hepatol. 2023;38:1316-1324.
    >> Share

  91. CHETWOOD JD, Sabih AH, Chan K, Salimi S, et al
    Epidemiology, characteristics, and outcomes of patients with acute-on-chronic liver failure in Australia.
    J Gastroenterol Hepatol. 2023;38:1325-1332.
    >> Share

    July 2023
  92. CHO MS, Lee SK, Kwon JH, Nam SW, et al
    Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis.
    J Gastroenterol Hepatol. 2023 Jul 10. doi: 10.1111/jgh.16277.
    >> Share

  93. CHOI WM, Yoo SY, Chang JI, Han S, et al
    A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization.
    J Gastroenterol Hepatol. 2023 Jul 7. doi: 10.1111/jgh.16280.
    >> Share

  94. PODDAR U, Samanta A, Sarma MS, Kumar B, et al
    How to suspect the presence of high-risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia?
    J Gastroenterol Hepatol. 2023 Jul 5. doi: 10.1111/jgh.16267.
    >> Share

  95. LIU M, Qiu H, Zhang W, Mei T, et al
    Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1018-1027.
    >> Share

  96. SHEN J, Cao J, Chen M, Zhang Y, et al
    Recent advances in the role of exosomes in liver fibrosis.
    J Gastroenterol Hepatol. 2023;38:1083-1088.
    >> Share

  97. SEDAROUS M, Youssef M, Adekunle AD, Babajide O, et al
    A nationwide study of liver disease hospitalizations during the coronavirus pandemic in the United States.
    J Gastroenterol Hepatol. 2023;38:1148-1157.
    >> Share

  98. JIANG N, Xiao Y, Yuan K, Wang Z, et al
    Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites.
    J Gastroenterol Hepatol. 2023;38:1056-1071.
    >> Share

    June 2023
  99. MINORETTI P, Emanuele E
    Reversing nonalcoholic fatty liver disease-related cirrhosis by inhibiting pyruvate kinase M2: a role for shikonin?
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16273.
    >> Share

  100. SHARMA BC, Maharshi S, Sachdeva S, Mahajan B, et al
    Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double-blind randomized controlled trial.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16266.
    >> Share

  101. GIRI S, Singh A, Kolhe K, Kale A, et al
    Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16263.
    >> Share

  102. ISHIBA H, Sumida Y, Kamada Y, Fujii H, et al
    Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
    J Gastroenterol Hepatol. 2023;38:896-904.
    >> Share

    May 2023
  103. DONG Y, Liu Y, Liu X, Ma H, et al
    Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures.
    J Gastroenterol Hepatol. 2023 May 24. doi: 10.1111/jgh.16221.
    >> Share

  104. WU CW, Wong GL, Wong VW, Yam TF, et al
    Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages.
    J Gastroenterol Hepatol. 2023 May 22. doi: 10.1111/jgh.16218.
    >> Share

  105. KIM DS, Kim BK, Lee JS, Lee HW, et al
    Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus-related liver cirrhosis.
    J Gastroenterol Hepatol. 2023 May 15. doi: 10.1111/jgh.16210.
    >> Share

  106. TIWARI A, Mehrotra M, Hasan A, Agarwal J, et al
    Hepatitis B virus liver decompensation: antiviral therapy for all.
    J Gastroenterol Hepatol. 2023;38:833-834.
    >> Share

  107. AHMED Z, Badal J, Nawras M, Battepati D, et al
    Role of rifaximin in the management of alcohol-associated hepatitis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:703-709.
    >> Share

    April 2023
  108. VERMA N, Vojjala N, Mishra S, Valsan A, et al
    Machine learning can guide suitability of consultation and patient referral through telemedicine for hepatobiliary diseases.
    J Gastroenterol Hepatol. 2023 Apr 28. doi: 10.1111/jgh.16194.
    >> Share

    March 2023
  109. MNATZAGANIAN G, MacLachlan JH, Allard N, Brown C, et al
    Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Mar 3. doi: 10.1111/jgh.16162.
    >> Share

  110. WONG GL
    Editorial: Appraising liver fibrosis with eagle eyes.
    J Gastroenterol Hepatol. 2023;38:343.
    >> Share

  111. ZHAO Q, Liang L, Zhai F, Ling G, et al
    A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022.
    J Gastroenterol Hepatol. 2023;38:359-369.
    >> Share

    February 2023
  112. ZHAO X, Shi X, Gu H, Zhou W, et al
    Association between handgrip strength, nonalcoholic fatty liver disease, advanced hepatic fibrosis and its modifiers: evidence from the NHANES database of the US.
    J Gastroenterol Hepatol. 2023 Feb 18. doi: 10.1111/jgh.16150.
    >> Share

    January 2023
  113. CHO SH, Song TJ, Park JS, Yoon JH, et al
    Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: a multicenter cohort study.
    J Gastroenterol Hepatol. 2023 Jan 29. doi: 10.1111/jgh.16136.
    >> Share

  114. BHATEJA A, Bodh V, Chauhan A
    Role of Nutrition in the management of hepatic encephalopathy - Do we know all?
    J Gastroenterol Hepatol. 2023 Jan 21. doi: 10.1111/jgh.16131.
    >> Share

  115. ZHANG Q, Jia R, Chen M, Wang J, et al
    Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and HSCs.
    J Gastroenterol Hepatol. 2023 Jan 18. doi: 10.1111/jgh.16126.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016